Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com


Rigorous science. Revolutionary solutions.

At Exact Sciences, we are committed to helping patients stay ahead of cancer. Our teams use their scientific expertise to practice innovation driven by robust research and cutting-edge science. We practice thorough, sound research that helps patients face challenging decisions with confidence.

Highlighted publications

Click on a cancer type or product below to view corresponding publications and abstracts

View all publications and abstracts »